State Street Corp Anavex Life Sciences Corp. Transaction History

State Street Corp

$2.59 Trillion
Q2 2025

A detailed history of State Street Corp transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, State Street Corp holds 2,948,808 shares of AVXL stock, worth $31.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,948,808

Previous 3,214,256 8.26%

Holding current value

$31.8 Million

Previous $27.6 Million 1.41%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$7.37 - $9.63 $1.96 Million - $2.56 Million	-265,448 Reduced 8.26%	2,948,808 $27.2 Million
Q1 2025 May 15, 2025	BUY	$7.85 - $13.46 $6.3 Million - $10.8 Million	802,327 Added 33.26%	3,214,256 $27.6 Million
Q4 2024 Feb 14, 2025	SELL	$5.11 - $12.56 $3.34 Million - $8.21 Million	-654,018 Reduced 21.33%	2,411,929 $25.9 Million
Q3 2024 Nov 14, 2024	SELL	$4.11 - $7.04 $2.77 Million - $4.75 Million	-674,409 Reduced 18.03%	3,065,947 $17.4 Million
Q2 2024 Aug 14, 2024	SELL	$3.39 - $5.02 $12.1 Million - $17.9 Million	-3,558,651 Reduced 48.76%	3,740,356 $15.8 Million
Q1 2024 May 15, 2024	BUY	$4.55 - $6.75 $16.6 Million - $24.7 Million	3,656,305 Added 100.37%	7,299,007 $37.2 Million
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $86,955 - $171,667	17,253 Added 0.48%	3,642,702 $33.9 Million
Q3 2023 Nov 14, 2023	SELL	$6.55 - $9.37 $5.13 Million - $7.34 Million	-783,488 Reduced 17.77%	3,625,449 $23.7 Million
Q2 2023 Aug 14, 2023	SELL	$7.66 - $9.5 $9.72 Million - $12.1 Million	-1,268,439 Reduced 22.34%	4,408,937 $35.8 Million
Q1 2023 May 15, 2023	SELL	$8.32 - $11.75 $1.13 Million - $1.59 Million	-135,229 Reduced 2.33%	5,677,376 $48.7 Million
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $11.1 Million - $20.9 Million	1,451,167 Added 33.27%	5,812,605 $53.8 Million
Q3 2022 Nov 15, 2022	SELL	$8.9 - $12.86 $1.14 Million - $1.64 Million	-127,807 Reduced 2.85%	4,361,438 $45 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $12.84 $7.95 Million - $14 Million	-1,088,011 Reduced 19.51%	4,489,245 $44.9 Million
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $17 Million - $30.8 Million	1,743,222 Added 45.47%	5,577,256 $68.7 Million
Q4 2021 Feb 14, 2022	SELL	$16.88 - $23.31 $5.59 Million - $7.72 Million	-331,386 Reduced 7.96%	3,834,034 $66.5 Million
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $1.57 Million - $2.41 Million	93,447 Added 2.29%	4,165,420 $74.8 Million
Q2 2021 Aug 16, 2021	BUY	$10.16 - $28.86 $13.5 Million - $38.2 Million	1,324,794 Added 48.22%	4,071,973 $93.1 Million
Q1 2021 May 17, 2021	BUY	$5.17 - $16.13 $9.68 Million - $30.2 Million	1,872,614 Added 214.12%	2,747,179 $41.1 Million
Q4 2020 Feb 16, 2021	SELL	$4.01 - $7.58 $63,859 - $120,711	-15,925 Reduced 1.79%	874,565 $4.72 Million
Q3 2020 Nov 10, 2020	BUY	$3.8 - $5.0 $53,652 - $70,595	14,119 Added 1.61%	890,490 $4.05 Million
Q2 2020 Aug 14, 2020	BUY	$2.62 - $5.2 $140,416 - $278,688	53,594 Added 6.51%	876,371 $4.31 Million
Q1 2020 May 11, 2020	BUY	$2.38 - $5.81 $1.96 Million - $4.78 Million	822,777 New	822,777 $2.59 Million

Others Institutions Holding AVXL

# of Institutions

196

Shares Held

31.8M

Call Options Held

1.16M

Put Options Held

804K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $840M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Anavex Life Sciences Corp. Transaction History